Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities
DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the Remuneration Committee has approved the grant of 3,431,350 share options (
Options ) to subscribe for ordinary shares in the Company (
Shares ) under the Employee Share Option Plan 2019 (the
Plan ) to Joe Wiley, CEO, and Rory Nealon, CFO, details of which are set out in the table below.
The Options have an exercise price of US$2.804 per Share ($14.02 per ADS equivalent) (
Amryt Supports Global Rare Disease Day 2021 pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Ovoca Bio is a European-based biopharmaceutical company with a focus on women s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD). The Company s lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD. Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.
Share:
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
DUBLIN, Ireland, and Boston MA, February 4, 2021, Amryt (NASDAQ:AMYT, AIM: AMYT)), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces the signing of multi-regional distribution agreements with Medison Pharma ( Medison ) to distribute Juxtapid® (lomitapide) in Canada and Lojuxta® (lomitapide) and Myalept® (metreleptin) in Israel.
Dr Joe Wiley, CEO of Amryt Pharma, commented today:
Today s announcement is another positive development as we continue to grow our commercial assets in existing and new territories and we further progress towards our goal of becoming a global leader in rare and orphan diseases. We are excited to be working with Medison to leverage their expertise and presence in these territories.
Dublin, Ireland, 25 January 2021 - Ovoca Bio plc (LSE: OVB; ISE: OVXA), a biopharmaceutical company with a focus on women s health, announces that an Extraordinary General Meeting of the Company will be held at 17 Pembroke Street Upper, Dublin 2, Ireland on 16 February 2021 at 11.00 am (the EGM ). The EGM is being convened to seek the approval of shareholders to certain resolutions which are intended to facilitate the migration of the Company s ordinary shares from the CREST System to the central securities depository ( CSD ) system operated by Euroclear Bank SA/NV, an international CSD incorporated in Belgium, following the withdrawal of the UK from the EU, and to make subsequent changes to the Company s Articles of Association (the Resolutions ).